Panbela Therapeutics, Inc.
PBLA · OTC
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $2 | $2 | $2 | $4,341 |
| - Cash | $0 | $0 | $0 | $3 |
| + Debt | $6 | $4 | $4 | $5 |
| Enterprise Value | $8 | $6 | $6 | $4,344 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$7 | -$8 | -$7 | -$7 |
| % Margin | – | – | – | – |
| EBITDA | -$7 | -$6 | -$7 | -$6 |
| % Margin | – | – | – | – |
| Net Income | -$7 | -$7 | -$7 | -$6 |
| % Margin | – | – | – | – |
| EPS Diluted | -1.48 | -1.47 | -2.28 | -0.027 |
| % Growth | -0.7% | 35.5% | -8,251.6% | – |
| Operating Cash Flow | -$2 | -$1 | -$9 | -$3 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$2 | -$1 | -$9 | -$3 |